Journals / Gülhane Tıp Dergisi / 2015 / Cilt: 57 - Sayı: 7

INCIDENCE OF PIPERACILLIN/TAZOBACTAM-INDUCED NEUTROPENIA IN PATIENTS WITH DIABETIC FOOT INFECTION: A RETROSPECTIVE COHORT STUDY

retrospektif kohort çalışma Diyabetik ayak enfeksiyonu nedeniyle piperasilin/ tazobactam tedavisi alan hastalarda nötropeni insidansı : retrospektif kohort çalışma

Pages
348–351
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, PTZ-induced neutropenia was identified in 6 of 31 treatments (19%).

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Piperacillin/tazobactam (PTZ) is frequently used in patients with diabetic foot infections (DFI).
📊
Key Findings & Data:We retrospectively reviewed the hospital records of patients who received PTZ for DFI between January 1st, 2006 and December 31st, 2012.
💡
Conclusion & Impact:Overall, PTZ-induced neutropenia was identified in 6 of 31 treatments (19%).
🔬Design:Review & Systematic Survey
📍Scope:2006 Verileri
⚙️Variables:Domain Parameters

Abstract

Piperacillin/tazobactam (PTZ) is frequently used in patients with diabetic foot infections (DFI). Prolonged use of PTZ may induce severe neutropenia. The aim of this study was to investigate the prevalence of PTZ induced neutropenia in patients with DFI. We retrospectively reviewed the hospital records of patients who received PTZ for DFI between January 1st, 2006 and December 31st, 2012. Patients who received PTZ for 10 days or more were included. Neutropenia was defined as an absolute neutrophil count of <2000 cells/mm3. PTZ-induced neutropenia was defined as neutropenia which developed during PTZ treatment, disappeared after the cessation of PTZ, and if differential diagnosis revealed no other cause of neutropenia. Thirty patients (13 females/17 males, mean age: 66.2 ± 9.4 years) with DFI had received PTZ for 10 days or more. One patient received PTZ at 2 different times. Overall, PTZ-induced neutropenia was identified in 6 of 31 treatments (19%). Additionally, thrombocytopenia accompanied neutropenia in three patients. Following the cessation of PTZ, within 10 days, neutropenia disappeared in all patients. In conclusion, prolonged PTZ use may induce neutropenia. Clinicians should follow patients with prolonged PTZ use.

Özet

Piperasilin/tazobaktam (PTZ) diyabetik ayak enfeksiyonlarının tedavisinde sıklıkla kullanılmaktadır. PTZ uzun süre kullanımında ciddi nötropeni oluşturabilmektedir. Bununla birlikte diyabetik ayak enfeksiyonlarında PTZ kullanımını öneren kılavuzlar bu ciddi yan etki hakkında çok az bilgi sunmaktadır. Bu çalışmanın amacı diyabetik ayak enfeksiyonu olan hastalarda PTZ kullanımına bağlı nötropeni gelişim insidansının tespit edilmesidir. 1 Ocak 2006 ve 31 Aralık 2012 yılları arasında diyabetik ayak enfeksiyonu nedeniyle PTZ tedavisi alan hastaların kayıtları retrospektif olarak incelenmiştir. On günden daha uzun süreli PTZ kullanan hastalar çalışmaya dahil edilmiştir. Tam kan sayımında nötrofil sayısının 2000 hücre/mm3'den az olması nötropeni olarak tanımlanmıştır. PTZ kullanımına bağlı nötropeni gelişimi: PTZ tedavisi sırasında gelişen, PTZ kesilmesi ile kaybolan ve nötropeniyi açıklayacak başka bir nedenin bulunmadığı durumlarda tanımlanmıştır. Çalışma döneminde 30 hastanın (13 erkek/17 kadın, yaş ortalaması: 66.2 ± 9.4) on gün veya daha uzun süre PTZ tedavisi aldığı tespit edildi. Bir hasta iki farklı dönemde PTZ tedavisi almıştı. Nötropeni 31 PTZ tedavisinin 6'sında (%19) tespit edildi. Üç hastada, ayrıca, trombositopeni gözlendi. PTZ kesildikten 1-10 gün sonra nötrofil sayıları normale döndü. Sonuç olarak uzun süreli PTZ tedavisi nötropeni riski taşımaktadır. Diyabetik ayak enfeksiyonu nedeniyle PTZ tedavisi planlanan hastalar nötropeni yan etkisi açısından sıkı takip edilmelidir.

🔖

Cite This Article

UZUN, G., MUTLUOĞLU, M., ÜLÇAY, A., Ay, H., MEMİŞ, A., KARAKAŞ, A., ÖZDEMİR, A., TURHAN, V. (2015). INCIDENCE OF PIPERACILLIN/TAZOBACTAM-INDUCED NEUTROPENIA IN PATIENTS WITH DIABETIC FOOT INFECTION: A RETROSPECTIVE COHORT STUDY. Gülhane Tıp Dergisi, Cilt: 57 - Sayı: 7, 348–351. https://ajindex.com/articles/204976

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Lavery LA, Armstrong DG, Wunderlich RP, Mohler MJ, Wendel CS, Lipsky BA. Risk factors for foot infections in individuals with diabetes. Diabetes Care. 2006;29:1288-1293
  2. Mutluoglu M, Sivrioglu AK, Eroglu M, et al. The implications of the presence of osteomyelitis on outcomes of infected diabetic foot wounds. Scand J Infect Dis. 2013;45:497-503
  3. Lipsky BA, Berendt AR, Cornia PB, Pile JC, Peters EJ, Armstrong DG, et al. 2012 Infectious Diseases Society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis. 2012; 54: e132-73
  4. Gin A, Dilay L, Karlowsky JA, Walkty A, Rubinstein E, Zhanel GG. Piperacillin-tazobactam: a beta-lactam/ beta-lactamase inhibitor combination. Expert Rev Anti Infect Ther. 2007; 5(3): 365-83
  5. Perry CM, Markham A. Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections. Drugs. 1999;57:805-43. 6
  6. Gerber L, Wing EJ. Life-threatening neutropenia secondary to piperacillin/tazobactam therapy. Clin. Infect. Dis. 1995;21:1047-8
  7. Salihoğlu M, Turhan V, Önem Y, Ulcay A, Uzun G, Ay H. Sudden hearing loss in a patient receiving piperacillin/ tazobactam and daptomycin for diabetic foot infection. Scand J Infect Dis. 2013;45(3):239-40
  8. Saltoglu N, Dalkiran A, Tetiker T, et al. Piperacillin/ tazobactam versus imipenem/cilastatin for severe diabetic foot infections: a prospective, randomized clinical trial in a university hospital. Clin Microbiol Infect. 2010;16(8):1252-7
  9. Weston BJ, Spackman VM, Dewdney JM. Beta-lactam antibiotics inhibit human in vitro granulopoiesis and proliferation of some other cell types. Cell Biol Toxicol. 1986;2(4):549-57
  10. Neftel KA, Hauser SP, Müller MR. Inhibition of granulopoiesis in vivo and in vitro by beta-lactam antibiotics. J Infect Dis. 1985;152:90-8
  11. Behbahani R, Kostman JR. Hypersensitivity reaction during prolonged use of piperacillin/tazobactam in treatment of osteomyelitis. Ann Pharmacother. 1995;29:936-7
  12. Uzun G, Onem Y, Hatipoglu M, Turhan V, Mutluoglu M, Ay H. Piperacillin/tazobactam-induced neutropenia, thrombocytopenia, and fever during treatment of a diabetic foot infection. Scand J Infect Dis. 2013 Jan;45(1):73-6
  13. Peralta FG, Sánchez MB, Roíz MP, Pena MA, Tejero MA, Arjona R. Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam. Clin. Infect. Dis. 2003;37:1568-72
  14. Hatipoglu M, Mutluoglu M, Uzun G, Karabacak E, Turh